A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
The current price of AstraZeneca PLC in the market is ¥27,262.2, with a 24-hour trading volume of ¥47.87B. The asset's market cap is ¥42.26T, after moving 2.37% in the last day.
Tokenized AstraZeneca PLC is trading at ¥15,033.08, with a tokenized market cap of ¥8.51B and a 24-hour trading volume of ¥127.25M. The tokenized asset has moved -2.12% in the past 24 hours.